Corcept Therapuetics About
Corcept: Corcept is a pharmaceutical company engaged
in the development of drugs for the treatment of severe psychiatric and neurological
diseases.Their lead product candidate is CORLUXTM, for the treatment of
the psychotic features of psychotic major depression, a disorder that affects
approximately three million people in the United States each year and for which
there are no FDA-approved treatments. They have also initiated a clinical study
to evaluate the tolerability and efficacy of their medicine in improving cognition
in patients with mild to moderate Alzheimer's disease. CORLUX, also
known as mifepristone, works by selectively blocking the binding of cortisol,
a steroid hormone, to one of its two known receptors. Elevated levels and abnormal
release patterns of cortisol have been implicated in a broad range of human disorders,
including PMD. By modifying the level and release pattern of cortisol within the
human body, Corcept believes that CORLUX will be able to treat the psychotic features
of PMD more quickly and effectively and with fewer side effects than is possible
with currently available treatments. More
on Corcept:
Key
Statistics for Corcept
Phase
III Corlux
( mifepristone)
Psychotic
major depression, Alzheimers
Basic
Chart for Corcept